Lineage Cell Therapeutics News

Buy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA Patients

TipRanksMay 8 00:35 ET

Maintained Buy Rating for Lineage Cell Therapeutics on Robust Clinical Trial Results and Strong Partnership With Roche

TipRanksMay 6 16:55 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaMay 6 10:37 ET

Optimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data Release

TipRanksMar 19 01:46 ET

Buy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy Advancements

TipRanksMar 11 00:35 ET

Optimistic Buy Rating for Lineage Cell Therapeutics Amid Pipeline Progress and Strategic Partnerships

TipRanksMar 8 12:45 ET

Buy Rating Affirmed for Lineage Cell Therapeutics Amid Strong Financials and Promising OpRegen Therapy Results

TipRanksMar 8 06:29 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaMar 8 06:11 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaFeb 13 12:37 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaFeb 5 09:25 ET

Buy Rating Affirmed for Lineage Cell Therapeutics Amid Promising Advances in Spinal Cord Injury Treatment

TipRanksDec 18, 2023 10:25 ET

Mayank Mamtani Assigns Buy Rating to Lineage Cell Therapeutics Citing Promising Clinical Results and Potential of Ongoing Trials

TipRanksOct 6, 2023 13:15 ET

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target

BenzingaAug 11, 2023 06:25 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaAug 11, 2023 06:24 ET

Cantor Fitzgerald Reiterates Overweight on Lineage Cell Therapeutics, Maintains $6 Price Target

BenzingaJul 25, 2023 07:56 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaJul 25, 2023 07:55 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaJul 24, 2023 12:53 ET

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target

BenzingaMay 12, 2023 06:34 ET

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target

BenzingaApr 26, 2023 06:15 ET

Maxim Group Sticks to Its Buy Rating for Lineage Cell Therapeutics (LCTX)

TipRanksJan 6, 2023 16:00 ET